Sector News

GE Healthcare’s CEO John Dineen to step down

October 9, 2014
Life sciences
GE Healthcare is changing up its leadership Monday, with current president and CEO John Dineen stepping down, effective immediately.
 
The top role will be filled by John Flannery, who was most recently the senior vice president of business development for GE, the company said.
 
The leadership shift is the latest to take place under chairman and CEO Jeff Immelt. Over the past 15 months, Immelt replaced top leaders at GE Capital and GE Oil & Gas and named Jeff Bornstein as the new chief financial officer of GE.
 
Dineen led the $20 billion health unit for seven years and worked within GE for 28 years. He previously held senior positions in GE Industrial Systems, Plastics, Transportation and Healthcare. Dineen is leaving the company to explore “new leadership opportunities,” according to the statement.
 
“John successfully led GE Healthcare during a period of growth, portfolio diversification and market volatility,” Jeff Immelt, GE chairman and CEO, said. “Thanks to his leadership, the business today is a global leader.”
 
GE Healthcare is the world’s leading manufacturer of medical imaging devices and also specializes in medical diagnostic tools and healthcare IT and software.
 
Flannery has been a key deal maker at GE this past year. He had a central role in GE’s recent purchase of France-based Alstom’s energy and transmission business as well as the spinoff of the company’s retail finance division, Synchrony Financial, which went public this year. He was also previously president and CEO of GE India and a senior leader at GE Capital.
 
By Laura Lorenzetti 
 
Source: Fortune

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach